'Excited to be back': Roche's sequel to failed Alzheimer's antibody looks promising in early study - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
A year ago, Roche’s future in Alzheimer’s disease looked uncertain. At an Alzheimer’s conference in San Francisco, the pharmaceutical company announced that its amyloid-targeting antibody gantenerumab failed to slow cognitive decline in a pivotal 2,000-patien…